---
document_datetime: 2026-02-03 10:33:10
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/uzprovo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: uzprovo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.320262
conversion_datetime: 2026-02-04 15:13:59.446629
docling_version:
  docling-serve: 1.11.0
  docling-jobkit: 1.9.1
  docling: 2.72.0
  docling-core: 2.63.0
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.12)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Uzpruvo

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                              |
|----------------------|-------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------------|
| Variation type IB /  | C.I.2 Change(s) in the Summary of Product | 22/12/2025                          | 30/01/2026                                  | SmPC and PL                      | To update Sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000316264   | SmPC and sections 2 and 3 of the Package Leaflet to include the indication 'treatment of moderately to severely active Crohn's disease in paediatric patients weighing at least 40 kg, who have had an inadequate response to, or were intolerant to either conventional or biologic therapy', following assessment of the same change for the reference product Stelara.   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                                       | PFS and 90 mg PFS • To delete '(legs)' after the injection site 'upper thigh' The MAA proposes to delete '(legs)' in section 2 of the Instructions for Administration/Use of the 45 mg vial, 45 mg PFS and 90 mg PFS line with Stelara • To make minor editorial changes in SmPC and PL in line with Stelara and QRD template for the EN Product Information and the translated Product Information (CS, DA, DE, ES, FI, FR, LT, LV, MT, NO, PT and RO).                                                                   |            |     |      |                                                                                                                             |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|-----------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000309634 | This was an application for a group of variations. B.II.b.4 Change in the batch size (including batch size ranges) of the finished product - B.II.b.4.f The scale for a biological/immunological medicinal product is increased / decreased without process change (e.g. duplication of line) - Accepted B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.a Minor change in the manufacturing process - Accepted | 26/11/2025 | N/A |      |                                                                                                                             |
| Variation type IB / EMA/VR/0000308833 | B.II.f.1.b Extension of the shelf life of the finished product - B.II.f.1.b.5 Extension of the shelf-life of a biological/ immunological                                                                                                                                                                                                                                                                                                                                                                                   | 11/11/2025 |     | SmPC | To extend the shelf-life of Uzpruvo 130 mg concentrate for solution for infusion (EU/1/23/1784/005), in accordance with the |

<div style=\"page-break-after: always\"></div>

|                                       | medicinal product in accordance with an approved stability protocol - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |     |                        | approved stability protocol, from 18 months to 24 months when stored at 2°C - 8°C, inclusive of 7 days of storage at room temperature up to 30°C.                                                                                                                                                                                        |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000269651 | B.II.d.1 Change in the specification parameters and/or limits of the finished product - B.II.d.1.e Change outside the approved specifications limits range - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 25/09/2025 | N/A |                        |                                                                                                                                                                                                                                                                                                                                          |
| Variation type IB / EMA/VR/0000268254 | C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2.a - To update sections 4.5 and 5.2 of the SmPC in order to add drug-drug interaction information based on results from study CNTO1275CRD1003, and sections 4.8 and 5.1 of the SmPC to include patient exposure numbers based on results from study CNTO1275UCO3001, following approval of the same change for the reference product Stelara. Additionally, the MAH took the opportunity to update the contact details for ET and LV in the list of local representatives and to align the | 16/05/2025 |     | SmPC, Labelling and PL | To update sections 4.5 and 5.2 of the SmPC in order to add drug-drug interaction information based on results from study CNTO1275CRD1003, and sections 4.8 and 5.1 of the SmPC to include patient exposure numbers based on results from study CNTO1275UCO3001, following approval of the same change for the reference product Stelara. |

<div style=\"page-break-after: always\"></div>

|                                       | wording for Figure 2 in the instructions for administration for the 45 mg vial presentation with the wording of the 45 mg pre-filled syringe. Furthermore, the MAH took the opportunity to make minor editorial amendments in the DA, ET, FI and PT product information for alignment with the QRD template and to correct the way one excipient is presented to align with other approved strengths.                           |            |     |      |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|
| Variation type IB / EMA/VR/0000261203 | B.II.f.1.b Extension of the shelf life of the finished product - B.II.f.1.b.5 Extension of the shelf-life of a biological/ immunological medicinal product in accordance with an approved stability protocol - Accepted                                                                                                                                                                                                         | 22/04/2025 |     | SmPC |
| Variation type IB / EMA/VR/0000255909 | This was an application for a group of variations. B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active | 18/03/2025 | N/A |      |

<div style=\"page-break-after: always\"></div>

|                                          | substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted                                                                                                                                                                                                                                                                                                          |            |     |    |
|------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----|
| Variation type IA_IN / EMA/VR/0000255737 | This was an application for a group of variations. B.II.b.2.c Replacement or addition of a manufacturer responsible for importation and/or batch release - B.II.b.2.c.1 Not including batch control/testing - Accepted B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging | 11/03/2025 |     | PL |
| Variation type IB / EMA/VR/0000246116    | B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.z Minor change in the manufacturing process of a sterile finished product after the primary packaging step - Accepted                                                                                                      | 18/02/2025 | N/A |    |